| Literature DB >> 31495688 |
Shangang Zhao1, Yi Zhu1, Robbie D Schultz2, Na Li3, Zhenyan He4, Zhuzhen Zhang1, Alexandre Caron5, Qingzhang Zhu1, Kai Sun6, Wei Xiong2, Hui Deng2, Jia Sun4, Yingfeng Deng1, Min Kim7, Charlotte E Lee5, Ruth Gordillo1, Tiemin Liu5, Angela K Odle8, Gwen V Childs8, Ningyan Zhang2, Christine M Kusminski1, Joel K Elmquist5, Kevin W Williams5, Zhiqiang An2, Philipp E Scherer9.
Abstract
The physiological role of leptin is thought to be a driving force to reduce food intake and increase energy expenditure. However, leptin therapies in the clinic have failed to effectively treat obesity, predominantly due to a phenomenon referred to as leptin resistance. The mechanisms linking obesity and the associated leptin resistance remain largely unclear. With various mouse models and a leptin neutralizing antibody, we demonstrated that hyperleptinemia is a driving force for metabolic disorders. A partial reduction of plasma leptin levels in the context of obesity restores hypothalamic leptin sensitivity and effectively reduces weight gain and enhances insulin sensitivity. These results highlight that a partial reduction in plasma leptin levels leads to improved leptin sensitivity, while pointing to a new avenue for therapeutic interventions in the treatment of obesity and its associated comorbidities.Entities:
Keywords: diabetes; hypothalamus; leptin; leptin resistance; obesity
Mesh:
Substances:
Year: 2019 PMID: 31495688 PMCID: PMC6774814 DOI: 10.1016/j.cmet.2019.08.005
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287